Stream Bio, a company that develops and manufactures a range of revolutionary bioimaging molecular probes, has won funding in the highly competitive Innovate UK, Manufacturing and Materials Innovation Loan Competition.
The loan will enable Stream Bio to facilitate the expansion of its Conjugated Polymer Nanoparticle (CPNTM) product range. This funding will also accelerate its successful commercialisation strategy by creating greater choice for research scientists.
Stream Bio will expand its product range by doubling the number of CPNTM products available with different wavelengths. Moreover, Stream Bio will increase its range of optional surface chemistries to enable linkage to other targeting molecules such as DNA, proteins and aptamers.
Stream Bio’s CPNs™ readily link to antibodies and are non-toxic, more sensitive, and more stable than conventional imaging reagents. These highly fluorescent nanoparticles are transforming the bioimaging market with their unique brightness, exceptional stability and magnetic capability. CPNs™ can be utilised in diagnostics and therapeutics, and have the potential to be used in tumour imaging and fluorescence-guided surgery. The wide variety of in-vitro diagnostic applications include flow cytometry, ELISA and fluorescent microscopy.
The manufacturing and materials innovation loan competition was part of a pilot funding programme from Innovate UK. The organisation offered up to £50 million in attractive loans across five industry sectors for highly innovative SMEs with transformative products.
Stream Bio’s CEO, Andy Chaloner, said: “Innovate UK’s pilot loan programme was introduced to help accelerate the growth of some of the country’s most transformative companies. We are delighted that Stream Bio’s innovative technology and potential ‘game changing’ impact on the sector has been recognised by such a highly competitive scheme. We are excited to use this investment to significantly expand our product range.”
News source: Stream Bio